SemBioSys announces 2007 financial and operation... (atements involve risks and uncertainties...)

SemBioSys announces 2007 financial and operational results

Date:3/17/2008

atements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Financial results included below:

SemBioSys Genetics Inc.

Consolidated Balance Sheets

As at December 31,

-------------------------------------------------------------------------

(expressed in Canadian dollars)

2007 2006

------------ ------------

$ $

Assets

Current assets

Cash and cash equivalents 20,444,013 16,328,459

Accounts receivable 583,591 526,002

Interest receivable 30,321 504,551

Prepaid expenses and deposits 538,718 392,094

Inventory 426,641 13,365

------------ ------------

22,023,284 17,764,471

Property
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
2. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
3. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys announces 2007 third quarter results
6. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
7. SemBioSys updates Apo AI development program
8. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
9. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
10. BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend
11. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results

Post Your Comments:

SemBioSys announces 2007 financial and operation...(atements involve risks and uncertainties...)